 |
市場調查報告書
商品編碼
1429275
寨卡病毒治療市場：現況分析與預測（2023-2030）Zika Virus Therapeutics Market: Current Analysis and Forecast (2023-2030) |
||||||
寨卡病毒主要透過家貓叮咬傳播。 它在 2015 年和 2016 年因其與受感染母親所生嬰兒的小頭畸形和其他出生缺陷相關而受到關注。 寨卡病毒治療的研究主要集中在疫苗和抗病毒藥物的開發。 疫苗開發的目的是創造一種安全有效的疫苗來預防寨卡病毒感染並預防出生缺陷，特別是孕婦。 症狀包括發燒、皮疹、關節疼痛和紅眼。 其他幾個因素，例如寨卡病毒感染數量的增加和水的不斷積累，正在推動全球對寨卡病毒治療的需求。 例如，根據泛美衛生組織的數據，2021年美洲地區共報告了1,430,922例蟲媒病毒性疾病病例，其中23,252例（1.6%）為寨卡病例。
由於全球家養貓蚊數量不斷增加，寨卡病毒治療市場預計將穩定成長約5.1%。 2022 年在坦尚尼亞進行的一項研究發現，在測試的總共 333 個盛水容器中，有 201 個（60.4%）至少有家貓幼蟲或蛹。 在預測期內，有幾個因素推動市場成長，包括蚊媒疾病盛行率上升、對蚊媒疾病的認識不斷提高以及醫療保健領域投資的增加。 除此之外，寨卡病毒療法提高治療效率的結果是治療程序更快、準確性更高，這也穩步推動了寨卡病毒療法市場的發展。
依疫苗類型，市場分為滅活疫苗、次單位疫苗、減毒疫苗等。 2022年，滅活疫苗領域在全球寨卡病毒治療市場中佔據最大份額，因為它可以有效增強人體對病毒的免疫力。 滅活疫苗使用殺死引起疾病的病毒和細菌的疫苗。 這些疫苗會刺激免疫反應，但不會引起疾病本身。 透過將滅活的病原體引入體內，免疫系統學會辨識並對抗特定的病毒和細菌，對未來的感染產生免疫力。 由此可見，2022年滅活疫苗領域將佔據較大市場份額。
根據最終用途，市場分為醫院、診所和其他。 到 2022 年，診所將佔據市場的主要份額。 診所是初級衛生保健機構，患者在這裡接受即時診斷、治療和持續護理。 我們透過提供最先進的醫療設施、專業知識和多學科的患者護理方法，在患者管理中發揮著至關重要的作用。 研究合作和收購的增加正在推動該領域的成長。 因此，診所類別在預測期內預計將出現更高的複合年增長率。
為了更了解茲卡病毒治療的市場介紹，市場包括北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度、亞太其他地區）和世界其他地區。 由於水污染加劇、庫蚊數量增加、蚊媒疾病病例增加以及開發有效寨卡病毒治療方法的投資增加，預計北美將在 2022 年超越目前的市場。 例如，根據美國衛生與公眾服務部的數據，截至 2020 年，美國大陸和美國領土上有 200 多種蚊子。 政府機構已啟動有關蚊媒疾病的宣傳計劃，以便為患者提供有效的治療。 因此，從地區來看，2022年北美將佔據較大市場份額。
市場上一些主要的參與者包括 Bharat Biotech、GeneOne Life Science、GSK plc、Hawaii Biotech Inc.、Leidos、INOVIO Pharmaceuticals、LUMOS PHARMA、Cytiva、Takeda Pharmaceutical 和 Cerus Corporation。
目錄
第一章市場介紹
- 市場定義
- 主要目標
- 利害關係人
- 限制
第二章研究方法或假設
- 調查過程
- 調查方法
- 受訪者簡介
第三章市場總結
第 4 章執行摘要
第五章 COVID-19 對茲卡病毒治療市場的影響
第六章寨卡病毒治療市場收入，2020-2030
第 7 章按疫苗類型劃分的市場洞察
- 滅活□□疫苗
- 次單位疫苗
- 減毒活疫苗
- 其他
第 8 章最終使用者的市場洞察
- 醫院
- 診所
- 其他
第 9 章按地區劃分的市場洞察
- 北美
- 美國
- 加拿大
- 其他北美地區
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲地區
- 亞太地區
- 中國
- 日本
- 印度
- 其他亞太地區
- 世界其他地區
第10章寨卡病毒治療藥物市場動態
- 市場驅動因素
- 市場挑戰
- 影響分析
第 11 章茲卡病毒治療市場機會
第十二章寨卡病毒治療藥物市場趨勢
第十三章需求方與供給方分析
- 需求方分析
- 供給面分析
第14章價值鏈分析
第15章競爭場景
- 競爭狀況
- 波特五力分析
第十六章公司簡介
- Bharat Biotech
- GeneOne Life Science
- GSK plc.
- Hawaii Biotech Inc.
- Leidos
- INOVIO Pharmaceuticals
- LUMOS PHARMA
- Cytiva
- Takeda Pharmaceutical Company Limited
- Cerus Corporation
第十七章免責聲明
The Zika virus is primarily transmitted through Aedes mosquito bites. It gained attention in 2015-2016 due to its link to birth defects like microcephaly in babies born to infected mothers. Research on Zika virus therapeutics is primarily focused on developing vaccines and antiviral drugs. Vaccine development aimed to create a safe and effective vaccine to prevent Zika virus infection, especially in pregnant women to protect against birth defects. Symptoms include fever, rash, joint pain, and red eyes. Several other factors, such as the rising cases of zika virus, and constant water accumulation are leading drivers of zika virus therapeutics globally. For instance, according to the Pan American Health Organization, in the Region of the Americas, in 2021, a total of 1,430,922 cases of arboviral disease were reported, of those 23,252 (1.6 %) were Zika cases.
The Zika Virus Therapeutics Market is expected to grow at a steady rate of around 5.1% owing to the rising Aedes mosquito population globally. According to the study performed in 2022 in Tanzania, a total of 333 water-holding containers were inspected and 201 (60.4%) had at least an Aedes larvae or pupae. Several factors, including a rising prevalence of mosquito-borne diseases, increasing awareness regarding mosquito-borne diseases, and increased investments in healthcare departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with zika virus therapeutics has resulted in faster treatment procedures and better accuracy which is also driving this market of zika virus therapeutics at a steady rate.
Based on vaccine type, the market is segmented into inactivated vaccine, subunit vaccine, live-attenuated vaccine, and others. The inactivated vaccine segment held the maximum share in the global market of zika virus therapeutics in 2022 owing to its efficiency in developing immunity in human body against the virus. Inactivated vaccines are created by using a killed version of the virus or bacteria that causes the disease. These vaccines stimulate an immune response without causing the disease itself. By introducing the inactivated pathogen to the body, the immune system learns to recognize and fight the specific virus or bacteria, providing immunity against future infections. Thus, the inactivated vaccine segment held a significant share of the market in 2022.
Based on end use, the market is segmented into hospitals, clinics, and others. The clinics held a significant share of the market in 2022. Clinics serve as primary healthcare institutions where patients receive an immediate diagnosis, treatment, and ongoing care. They play a pivotal role in the management of patients by providing state-of-the-art medical facilities, specialized expertise, and a multidisciplinary approach to patient care. Rising collaborations and acquisitions are boosting this segment's growth. Hence, the clinics category is expected to witness higher CAGR during the forecast period.
For a better understanding of the market adoption of zika virus therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing water pollution, rising Aedes mosquito population, increasing cases of mosquito-borne diseases, and rising number of investments in developing effective zika virus therapeutics. For example, in 2020, according to U.S. Department of Health & Human Services, over 200 types of mosquitoes live in the continental U.S. and U.S. territories; of these 200, about 12 types spread germs that can make people sick. Government organizations are initiating mosquito-borne diseases awareness programs to provide efficient care to patients. Thus, amongst regions, North America held a significant share of the market in 2022.
Some of the major players operating in the market include Bharat Biotech; GeneOne Life Science; GSK plc.; Hawaii Biotech Inc.; Leidos; INOVIO Pharmaceuticals; LUMOS PHARMA; Cytiva; Takeda Pharmaceutical Company Limited; Cerus Corporation.
TABLE OF CONTENTS
1 MARKET INTRODUCTION
- 1.1. Market Definitions
- 1.2. Main Objective
- 1.3. Stakeholders
- 1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
- 2.1. Research Process of the Zika Virus Therapeutics Market
- 2.2. Research Methodology of the Zika Virus Therapeutics Market
- 2.3. Respondent Profile
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 IMPACT OF COVID-19 ON THE ZIKA VIRUS THERAPEUTICS MARKET
6 ZIKA VIRUS THERAPEUTICS MARKET REVENUE (USD BN), 2020-2030F
7 MARKET INSIGHTS BY VACCINE TYPE
- 7.1. Inactivated Vaccine
- 7.2. Subunit Vaccine
- 7.3. Live-attenuated Vaccine
- 7.4. Others
8 MARKET INSIGHTS BY END-USER
- 8.1. Hospitals
- 8.2. Clinics
- 8.3. Others
9 MARKET INSIGHTS BY REGION
- 9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
- 9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
- 9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
- 9.4. Rest of World
10 ZIKA VIRUS THERAPEUTICS MARKET DYNAMICS
- 10.1. Market Drivers
- 10.2. Market Challenges
- 10.3. Impact Analysis
11 ZIKA VIRUS THERAPEUTICS MARKET OPPORTUNITIES
12 ZIKA VIRUS THERAPEUTICS MARKET TRENDS
13 DEMAND AND SUPPLY-SIDE ANALYSIS
- 13.1. Demand Side Analysis
- 13.2. Supply Side Analysis
14 VALUE CHAIN ANALYSIS
15 COMPETITIVE SCENARIO
- 15.1. Competitive Landscape
- 15.1.1. Porters Fiver Forces Analysis
16 COMPANY PROFILED
- 16.1. Bharat Biotech
- 16.2. GeneOne Life Science
- 16.3. GSK plc.
- 16.4. Hawaii Biotech Inc.
- 16.5. Leidos
- 16.6. INOVIO Pharmaceuticals
- 16.7. LUMOS PHARMA
- 16.8. Cytiva
- 16.9. Takeda Pharmaceutical Company Limited
- 16.10. Cerus Corporation
